Evidence map›Paper›PMID 41571952›Full record

ArticleMolecular neurobiology2026

Synergistic Neuroprotection of Combined Shenmai and Hypothermia in Cerebral Ischemia-Reperfusion Injury via ERK-Dependent Anti-inflammatory Effects.

Yuan Wang, Hangui Ren, Yufei Qiu, Rongchen Dai, Mengfan Liu, Shiting Mo, Yibo Zhang, Wang Fu, Qianqian Bi, Yongpeng Wang and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuan Wang *Department of Neurology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
Hangui Ren *School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yufei QiuDepartment of Neurology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
Rongchen DaiSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Mengfan LiuSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Shiting MoDepartment of Neurology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
Yibo ZhangSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Wang FuDepartment of Neurology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
Qianqian BiDepartment of Neurology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
Yongpeng WangDepartment of Neurology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
Yunuo ZhouTaylors College Sydney, The University of Sydney, Waterloo, NSW, 2017, Australia.
Zhichao XiSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. xizhichao@shutcm.edu.cn.
Hongxi XuSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. hxxu@shutcm.edu.cn.
Feng WangDepartment of Neurology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China. wangfengshutcm@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral ischemia-reperfusion (I/R) injury remains a major challenge in patients with ischemic stroke undergoing endovascular thrombectomy (EVT). Although selective intraarterial hypothermia has shown neuroprotective potential, its therapeutic efficacy is limited, highlighting the need for effective pharmacological adjuncts. This study investigated whether combining intracarotid hypothermia with Shenmai could synergistically enhance neuroprotection against cerebral I/R injury. Cold Shenmai (4 °C) or saline was infused into rat brain. Systemic toxicity was assessed by body weight, serum biochemistry, organ morphology, and indices. Brain toxicity was evaluated with 2,3,5-triphenyltetrazolium chloride (TTC), hematoxylin and eosin (H&E), and Fluoro-Jade B (FJB) staining. Cerebral I/R injury was induced by middle cerebral artery occlusion (MCAO). Neuroprotection was assessed by TTC staining, neurological deficit score, rotarod, adhesive removal, and by H&E, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and Nissl staining. RNA sequencing explored mechanisms. Inflammatory cytokines were quantified by quantitative real-time polymerase chain reaction (qRT-PCR), while extracellular signal-regulated kinase (ERK) and nuclear factor kappa-B (NF-κB) signaling were examined by Western blot and immunofluorescence. The ERK inhibitor PD98059 verified mechanistic contributions. Cold Shenmai infusion showed no evidence of systemic or cerebral toxicity. Compared with cold saline, it significantly reduced infarct volume, improved neurological function and behavioral outcomes, and attenuated neuronal damage. Transcriptomic analysis revealed downregulation of pro-inflammatory pathways and reduced expression of microglial activation-related signaling. Mechanistically, cold Shenmai enhanced ERK1/2 phosphorylation, which was associated with reduced microglial marker expression and suppressed NF-κB P65 nuclear translocation. Importantly, these protective effects were markedly attenuated by the ERK1/2 inhibitor PD98059, indicating that ERK signaling plays a critical role in mediating the anti-inflammatory and neuroprotective effects of cold Shenmai during cerebral I/R injury. Intracarotid Shenmai with hypothermia synergistically attenuates cerebral I/R injury through ERK-mediated anti-inflammatory effects, including reduced microglial activation markers. These findings provide mechanistic preclinical evidence supporting Shenmai as an effective pharmacological adjunct to intraarterial hypothermia and suggest a promising therapeutic approach for mitigating reperfusion injury following EVT in acute ischemic stroke.

Indexed as

Anti-Inflammatory AgentsBrain IschemiaDrugs, Chinese HerbalExtracellular Signal-Regulated MAP KinasesHypothermia, InducedMAP Kinase Signaling SystemNeuroprotectionNeuroprotective AgentsReperfusion InjuryAnimalsBrainDrug CombinationsInfarction, Middle Cerebral ArteryMaleRatsRats, Sprague-DawleyAnti-Inflammatory AgentsDrug CombinationsDrugs, Chinese HerbalExtracellular Signal-Regulated MAP Kinasesfructus schizandrae, radix ginseng, radix ophiopogonis drug combinationNeuroprotective AgentsCerebral ischemia-reperfusion injuryERKHypothermiaMicroglia activation markersNeuroinflammationShenmai

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.